Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 120552
1. Kim J, Park JS, Ham WS: The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer. Investig Clin Urol; 2017 Sep;58(5):307-316

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.
  • Oligometastasis has been proposed as an intermediate stage of cancer spread between localized disease and widespread metastasis.
  • The importance of oligometastasis in managing metastatic prostate cancer is that it is possible to treat with a curative aim by metastasis-directed or local therapy in selected patients.
  • However, few studies have shown definitive benefits of metastasis-directed or local therapy in oligometastatic prostate cancer.
  • Review of the available studies suggests that stereotactic radiotherapy (RT) of metastatic lesions in oligorecurrent disease is a feasible and safe modality for managing oligometastatic prostate cancer.
  • Many retrospective studies of metastatic prostate cancer have shown that patients undergoing local therapy seem to have superior overall and cancer-specific survival compared with patients not receiving local therapy.
  • Ongoing prospective randomized trials would be helpful to evaluate the role of local therapy in oligometastatic prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1998 Oct 8;339(15):1036-42 [9761805.001]
  • [Cites] Front Oncol. 2013 Jan 22;2:215 [23346551.001]
  • [Cites] Arch Intern Med. 2006 Feb 27;166(4):465-71 [16505268.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23 ):1655-9 [11759643.001]
  • [Cites] J Clin Oncol. 2016 May 10;34(14 ):1652-9 [26951312.001]
  • [Cites] Lancet. 2011 Dec 17;378(9809):2104-11 [22056152.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3475-84 [15337795.001]
  • [Cites] J Urol. 2004 Apr;171(4):1393-401 [15017184.001]
  • [Cites] Rev Urol. 2007;9 Suppl 1:S3-8 [17387371.001]
  • [Cites] Lancet. 2009 Jan 24;373(9660):301-8 [19091394.001]
  • [Cites] Eur Urol. 2015 Jul;68(1):32-9 [25457017.001]
  • [Cites] Asian J Androl. 2012 Mar;14(2):226-31 [22231296.001]
  • [Cites] Eur Urol. 2014 Aug;66(2):243-50 [24680359.001]
  • [Cites] Cell. 2009 Dec 24;139(7):1315-26 [20064377.001]
  • [Cites] Urol Oncol. 2006 Sep-Oct;24(5):396-402 [16962488.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2727-31 [7743477.001]
  • [Cites] Cancer. 1988 Jan 1;61(1):195-202 [3334948.001]
  • [Cites] J Urol. 2004 Aug;172(2):525-8 [15247720.001]
  • [Cites] Nat Rev Clin Oncol. 2011 Jun;8(6):378-82 [21423255.001]
  • [Cites] J Urol. 2002 Sep;168(3):1008-12 [12187210.001]
  • [Cites] J Natl Cancer Inst. 2015 May 09;107(7):null [25957435.001]
  • [Cites] Clin Genitourin Cancer. 2013 Mar;11(1):27-32 [23010414.001]
  • [Cites] Acta Oncol. 2013 Nov;52(8):1622-8 [23544357.001]
  • [Cites] J Clin Invest. 2013 Nov;123(11):4918-22 [24135135.001]
  • [Cites] J Hematol Oncol. 2012 Jun 28;5:34 [22742411.001]
  • [Cites] Clin Genitourin Cancer. 2013 Dec;11(4):375-84 [23891497.001]
  • [Cites] Eur Urol. 2014 Sep;66(3):602-3 [24821581.001]
  • [Cites] J Urol. 2015 Aug;194(2):378-85 [25711194.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):3-10 [14697414.001]
  • [Cites] Cancer. 2009 Jun 1;115(11):2388-99 [19399748.001]
  • [Cites] J Urol. 2008 Jun;179(6):2212-6; discussion 2216-7 [18423716.001]
  • [Cites] Eur Urol. 2014 Jun;65(6):1058-66 [24290503.001]
  • [Cites] Eur Urol. 2015 May;67(5):819-22 [25246081.001]
  • [Cites] PLoS One. 2016 Jan 25;11(1):e0147191 [26807740.001]
  • [Cites] Eur Urol. 2012 Aug;62(2):213-9 [22502942.001]
  • [Cites] Eur Urol. 2014 Feb;65(2):467-79 [24321502.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1064-73 [24661660.001]
  • [Cites] Eur Urol. 2016 Jan;69(1):9-12 [26189689.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):889-97 [21277113.001]
  • [Cites] Eur Urol. 2011 May;59(5):832-40 [21354694.001]
  • [Cites] JAMA. 2005 Jul 13;294(2):238-44 [16014598.001]
  • [Cites] Eur Urol. 2010 May;57(5):754-61 [20106588.001]
  • [Cites] Prostate. 2017 May;77(6):559-572 [28093791.001]
  • [Cites] Lancet Oncol. 2010 Nov;11(11):1066-73 [20933466.001]
  • [Cites] Lancet. 2012 Dec 8;380(9858):2018-27 [23084481.001]
  • [Cites] J Urol. 2012 Dec;188(6):2219-24 [23083655.001]
  • [Cites] Cancer Epidemiol. 2014 Aug;38(4):435-41 [24802851.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90 [15817329.001]
  • [Cites] Lancet Oncol. 2008 Aug;9(8):808 [18672217.001]
  • [Cites] Eur Urol. 2015 Aug;68(2):325-34 [25108577.001]
  • [Cites] Eur Urol. 2014 Jan;65(1):124-37 [24207135.001]
  • [Cites] JAMA. 1996 Oct 23-30;276(16):1309-15 [8861989.001]
  • [Cites] Radiother Oncol. 2009 Oct;93(1):14-7 [19409636.001]
  • [Cites] Eur Urol. 2017 Aug;72 (2):289-292 [27574820.001]
  • [Cites] Prostate. 2014 Feb;74(3):297-305 [24395565.001]
  • [Cites] Radiat Oncol. 2014 Jun 12;9:135 [24920079.001]
  • [Cites] Urol Oncol. 2013 May;31(4):455-60 [21481619.001]
  • [Cites] J Urol. 2015 Mar;193(3):832-8 [25254935.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):8-10 [7799047.001]
  • (PMID = 28868501.001).
  • [ISSN] 2466-054X
  • [Journal-full-title] Investigative and clinical urology
  • [ISO-abbreviation] Investig Clin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Korea (South)
  • [Keywords] NOTNLM ; Neoplasm metastasis / Prostatectomy / Prostatic neoplasms / Radiotherapy
  •  go-up   go-down


2. Cagney DN, Dunne M, O'Shea C, Finn M, Noone E, Sheehan M, McDonagh L, O'Sullivan L, Thirion P, Armstrong J: Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy. BMC Urol; 2017 Aug 01;17(1):60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy.
  • BACKGROUND: Our aim was to assess the heterogeneity of high-risk (HR) prostate cancer managed with high-dose external beam radiotherapy (EBRT) with androgen deprivation therapy (ADT).
  • On multivariate analysis, significant predictors of shorter bRFS were biopsy Gleason score (bGS) of 8 to 10, higher prostate-specific antigen (PSA) level, shorter duration of ADT and lower radiation dose while predictors of shorter DMFS were bGS of 8 to 10, higher PSA level, and lower radiation dose.
  • We identified an unfavorable high-risk (UHR) group of with 2-3 HR factors based on 2015 National Comprehensive Cancer Network (NCCN) criteria and a favorable high-risk (FHR) group, with 1 HR feature.
  • Comparing very-HR prostate cancer, UHR & FHR, 5 year bRFS rates were 58.2%, 66.2%, and 69.2%, and 5 year DMFS rates were 78.4%, 81.2%, and 88.0%.
  • Future studies should account for this heterogeneity in HR prostate cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):609-15 [10837943.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):103-6 [12126818.001]
  • [Cites] J Urol. 2005 Jun;173(6):1938-42 [15879786.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2597-603 [17039498.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):980-8 [18495377.001]
  • [Cites] J Urol. 2007 Jun;177(6):2106-31 [17509297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1397-404 [21665379.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):254-62 [26853334.001]
  • [Cites] Eur Urol. 2010 Jul;58(1):1-7; discussion 10-1 [20299147.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):125-30 [19695789.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 2):S16-20 [17084158.001]
  • [Cites] N Engl J Med. 2009 Jun 11;360(24):2516-27 [19516032.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74 [17765406.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2014 Mar;17(1):57-63 [24189998.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):330-7 [18164858.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2497-504 [18413638.001]
  • [Cites] JAMA. 2004 Aug 18;292(7):821-7 [15315996.001]
  • [Cites] Cancer. 2009 Jul 1;115(13 Suppl):3112-20 [19544539.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):828-35 [26530751.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74 [16798415.001]
  • [Cites] Lancet Oncol. 2007 Jun;8(6):475-87 [17482880.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90 [15817329.001]
  • [Cites] BJU Int. 2011 Mar;107(5):765-770 [20875089.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1028-33 [18280056.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1233-9 [16160131.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1419-23 [19131185.001]
  • [Cites] J Clin Oncol. 2015 Apr 20;33(12 ):1356-63 [25624432.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1141-8 [22099043.001]
  • [Cites] JAMA. 1998 Sep 16;280(11):969-74 [9749478.001]
  • (PMID = 28764689.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Tanaka N, Asakawa I, Nakai Y, Miyake M, Anai S, Fujii T, Hasegawa M, Konishi N, Fujimoto K: Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer. BMC Cancer; 2017 Aug 25;17(1):573
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.
  • BACKGROUND: To compare the PSA value at the last follow-up of patients who underwent prostate low-dose rate brachytherapy (LDR-BT) with that of patients who underwent intensity-modulated radiation therapy (IMRT).
  • METHODS: A total of 610 prostate cancer patients (cT1c-3bN0M0) were enrolled, and 445 of them underwent LDR-BT, while 165 received IMRT (74-76 Gy).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2014 Sep;114(3):360-7 [24447404.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):87-93 [24331654.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):36-42 [19409729.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1336-42 [20605342.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):527-33 [16242258.001]
  • [Cites] J Urol. 2013 Mar;189(3):878-83 [23103235.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):528-34 [11792912.001]
  • [Cites] Radiat Oncol. 2014 May 06;9:107 [24885896.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):600-7 [21985944.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):57-64 [17084544.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1310-7 [20493642.001]
  • [Cites] J Urol. 2003 Feb;169(2):517-23 [12544300.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):355-60 [19632069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2017 Jun 1;98 (2):275-285 [28262473.001]
  • [Cites] Urology. 2011 Apr;77(4):986-90 [21195465.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74 [16798415.001]
  • [Cites] Int J Urol. 2009 Jan;16(1):70-4 [19120529.001]
  • [Cites] BJU Int. 2012 Feb;109 Suppl 1:22-9 [22239226.001]
  • [Cites] JAMA. 1998 Sep 16;280(11):969-74 [9749478.001]
  • (PMID = 28841855.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; BED / Biochemical recurrence-free rate / IMRT / Low-dose rate brachytherapy / Prostate cancer / Testosterone
  •  go-up   go-down


Advertisement
4. Pettersson A, Gerke T, Penney KL, Lis RT, Stack EC, Pértega-Gomes N, Zadra G, Tyekucheva S, Giovannucci EL, Mucci LA, Loda M: MYC overexpression at the protein and mRNA level and cancer outcomes among men treated with radical prostatectomy for prostate cancer. Cancer Epidemiol Biomarkers Prev; 2017 Nov 15;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC overexpression at the protein and mRNA level and cancer outcomes among men treated with radical prostatectomy for prostate cancer.
  • BACKGROUND: The proto-oncogene MYC is implicated in prostate cancer progression.
  • Whether MYC tumor expression at the protein or mRNA level is associated with poorer prognosis has not been well studied.
  • METHODS: We conducted a cohort study including 634 men from the Physicians' Health Study and Health Professionals Follow-up Study treated with radical prostatectomy for prostate cancer in 1983-2004 and followed-up for a median of 13.7 years.
  • MYC protein expression was evaluated using immunohistochemistry, and we used Cox regression to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) of its association with lethal prostate cancer (distant metastases/prostate cancer death).
  • We assessed the association between MYC mRNA expression and lethal prostate cancer in a case-control study including 113 lethal cases and 291 indolent controls.
  • MYC protein expression was positively correlated with tumor proliferation rate (r=0.37; p<0.001) and negatively correlated with apoptotic count (r=-0.17; p<0.001).
  • There were no significant associations between MYC protein expression and stage, grade or PSA level at diagnosis.
  • The multivariable HR for lethal prostate cancer among men in the top versus bottom quartile of MYC protein expression was 1.09 (95% CI: 0.50-2.35).
  • There was no significant association between MYC mRNA expression and lethal prostate cancer.
  • CONCLUSION: Neither MYC protein overexpression nor MYC mRNA overexpression are strong prognostic markers in men treated with radical prostatectomy for prostate cancer.
  • IMPACT: This is the largest study to examine the prognostic role of MYC protein and mRNA expression in prostate cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright ©2017, American Association for Cancer Research.
  • (PMID = 29141848.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF 3rd, King MT: Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. Int J Radiat Oncol Biol Phys; 2017 Nov 15;99(4):904-911
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.
  • PURPOSE: A recent randomized controlled trial demonstrated that the addition of external beam radiation therapy (EBRT) to brachytherapy did not improve progression-free survival in select patients with intermediate-risk prostate cancer.
  • We evaluated whether the addition of EBRT to brachytherapy improves prostate cancer-specific mortality (PCSM) for intermediate- and high-risk disease using a large national database.
  • METHODS AND MATERIALS: We identified 5836 patients in the Surveillance, Epidemiology, and End Results-Medicare linked database with a diagnosis of National Comprehensive Cancer Network intermediate-risk (Gleason score 7, prostate-specific antigen 10-20 ng/mL, or stage cT2b-T2c) or high-risk (Gleason score 8-10 or prostate-specific antigen >20 ng/mL and stage ≤cT3a) prostate cancer who had undergone brachytherapy, with or without EBRT and androgen deprivation therapy (ADT).
  • CONCLUSIONS: These results suggest that certain patients with intermediate- or high-risk prostate cancer treated with brachytherapy might not benefit from the addition of EBRT.
  • A randomized controlled trial of brachytherapy plus ADT with or without EBRT for unfavorable intermediate- and favorable high-risk organ-confined prostate cancer should be undertaken.
  • [MeSH-major] Brachytherapy. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy / methods. Databases, Factual. Humans. Male. Neoplasm Grading. Propensity Score. SEER Program

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 29063853.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Shah TT, To WKL, Ahmed HU: Magnetic resonance imaging in the early detection of prostate cancer and review of the literature on magnetic resonance imaging-stratified clinical pathways. Expert Rev Anticancer Ther; 2017 Dec;17(12):1159-1168

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging in the early detection of prostate cancer and review of the literature on magnetic resonance imaging-stratified clinical pathways.
  • INTRODUCTION: With level 1 evidence now available on the diagnostic accuracy of multiparametric magnetic resonance imaging (MRI) we must now utilise this data in developing an MRI-stratified diagnostic pathway for the early detection of prostate cancer.
  • Areas covered: A literature review was conducted and identified seven randomised control trials (RCT's) assessing the diagnostic accuracy of such a pathway against the previously accepted systematic/random trans-rectal ultrasound guided (TRUS) biopsy pathway.
  • Five studies assessed the addition of MRI-targeted biopsies to a standard care systematic TRUS biopsy pathway.
  • Two studies looked specifically at a targeted biopsy only pathway and although the results were again mixed, there was no decrease in the diagnostic rate and overall significantly fewer biopsy cores were taken in the MRI group.
  • Expert commentary: Results from these RCT's together with multiple retrospective and prospective studies point towards either an improved diagnostic rate for clinically significant cancer and/or a reduction in the need for systematic biopsies with a MRI-stratified pathway.
  • The challenge for the urological community will be to implement pre-biopsy MRI into a routine clinical pathway with likely independent monitoring of standards.
  • [MeSH-major] Early Detection of Cancer / methods. Magnetic Resonance Imaging / methods. Prostatic Neoplasms / diagnostic imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28933973.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Keywords] NOTNLM ; MRI / diagnosis / pathway / prostate cancer / review
  •  go-up   go-down


7. Paydar I, Pepin A, Cyr RA, King J, Yung TM, Bullock EG, Lei S, Satinsky A, Harter KW, Suy S, Dritschilo A, Lynch JH, Kole TP, Collins SP: Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity. Front Oncol; 2017;7:5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.
  • BACKGROUND: Recent data suggest that intensity-modulated radiation therapy (IMRT) plus brachytherapy boost for unfavorable prostate cancer provides improved biochemical relapse-free survival over IMRT alone.
  • MATERIALS AND METHODS: Between March 2008 and September 2012, patients with prostate cancer were treated with robotic SBRT (19.5 Gy in three fractions) followed by fiducial-guided IMRT (45-50.4 Gy) on an institutional protocol.
  • Toxicity was prospectively graded using the common terminology criteria for adverse events version 4.0 (CTCAEv.4) at the start of and at 1- to 6-month intervals after therapy.
  • Future studies should compare cancer control, quality of life, and toxicity with other treatment modalities for patients with high-risk prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Technol Cancer Res Treat. 2010 Oct;9(5):453-62 [20815416.001]
  • [Cites] Front Oncol. 2016 May 06;6:114 [27200300.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):150-4 [16111583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):937-9 [26530768.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):285-95 [9572622.001]
  • [Cites] J Urol. 2015 Dec;194(6):1624-30 [26165583.001]
  • [Cites] Radiat Oncol. 2016 Jan 21;11:8 [26792201.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9 [22330997.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):751-8 [20207506.001]
  • [Cites] Technol Cancer Res Treat. 2010 Dec;9(6):575-82 [21070079.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1192-9 [15718316.001]
  • [Cites] Radiother Oncol. 2012 Jul;104(1):114-8 [22727264.001]
  • [Cites] Radiat Oncol. 2013 Mar 13;8:58 [23497695.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55 [15001244.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):1990-6 [16648499.001]
  • [Cites] Urology. 2000 Dec 20;56(6):899-905 [11113727.001]
  • [Cites] Acta Oncol. 2005;44(3):265-76 [16076699.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):316-27 [12023135.001]
  • [Cites] Cancer. 2015 Jul 15;121(14):2422-30 [25847819.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):999-1007 [16750320.001]
  • [Cites] Urology. 2000 Mar;55(3):382-6 [10699615.001]
  • [Cites] Radiat Oncol. 2013 Jan 31;8:30 [23369294.001]
  • [Cites] Radiother Oncol. 2012 May;103(2):217-22 [22341794.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82 [21300474.001]
  • [Cites] Cancer. 2013 Feb 1;119(3):681-90 [22893254.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):383-7 [18947938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74 [17765406.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2630-7 [10375112.001]
  • [Cites] J Urol. 2016 Jun;195(6):1811-6 [26778712.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):679-85 [22954770.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1443-53 [27325475.001]
  • [Cites] Radiother Oncol. 2000 Jan;54(1):11-9 [10719695.001]
  • [Cites] Radiat Oncol. 2014 Jan 01;9:1 [24382205.001]
  • [Cites] Br J Radiol. 2015 Oct;88(1054):20140736 [26235142.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Aug 1;92 (5):971-7 [26054865.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):932-8 [24113055.001]
  • [Cites] Front Oncol. 2014 Oct 31;4:278 [25401085.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 2):S21-5; discussion S26-7 [14610406.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55 [17531401.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1306-16 [15817332.001]
  • [Cites] Radiat Oncol. 2014 Dec 12;9:277 [25497602.001]
  • [Cites] Radiother Oncol. 2009 May;91(2):232-6 [19097660.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5366-73 [18048817.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1233-9 [16160131.001]
  • [Cites] Front Oncol. 2015 Sep 01;5:194 [26389077.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):184-91 [12694837.001]
  • [Cites] J Urol. 2007 Jan;177(1):123-7; discussion 127 [17162020.001]
  • (PMID = 28224113.001).
  • [ISSN] 2234-943X
  • [Journal-full-title] Frontiers in oncology
  • [ISO-abbreviation] Front Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; CyberKnife / IMRT / SBRT / common terminology criteria / prostate cancer
  •  go-up   go-down


8. Zakaria A, Al Share B, Kollepara S, Vakhariya C: External Beam Radiation and Brachytherapy for Prostate Cancer: Is It a Possible Trigger of Large Cell Neuroendocrine Carcinoma of the Urinary Bladder? Case Rep Oncol Med; 2017;2017:1853985

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External Beam Radiation and Brachytherapy for Prostate Cancer: Is It a Possible Trigger of Large Cell Neuroendocrine Carcinoma of the Urinary Bladder?
  • Among those, large cell neuroendocrine carcinoma (LCNEC) is the least common, is more aggressive, and generally presents in an advanced stage with poor prognosis compared to transitional cell bladder carcinoma.
  • There is no standardized treatment regimen because of the rarity of the disease.
  • Herein, we present a case of 72-year-old male patient with previously treated prostate cancer, who received external beam radiation therapy and high dose brachytherapy, presenting with intermittent hematuria.
  • Cystoscopy and transurethral resection of bladder tumor (TURBT) were performed.
  • The histopathology and immunohistochemistry were consistent with large cell neuroendocrine carcinoma (LCNEC).
  • Further studies are required to proof the higher risk of neuroendocrine carcinoma of the bladder in patients treated with external beam radiation therapy and brachytherapy for prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2007 Nov;128(5):733-9 [17951193.001]
  • [Cites] Clin Genitourin Cancer. 2013 Jun;11(2):73-7 [23266053.001]
  • [Cites] Arch Esp Urol. 2011 Mar;64(2):105-13 [21399243.001]
  • [Cites] Curr Urol. 2013 Feb;7(3):155-9 [24917779.001]
  • [Cites] Rare Tumors. 2014 Jan 23;6(1):5043 [24711904.001]
  • [Cites] Arch Pathol Lab Med. 2002 Oct;126(10):1229-32 [12296766.001]
  • [Cites] J Urol. 1998 May;159(5):1624-9 [9554367.001]
  • [Cites] Diagn Pathol. 2013 Feb 04;8:19 [23379295.001]
  • [Cites] Pathol Int. 2006 Nov;56(11):688-93 [17040293.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):1016-20 [9796733.001]
  • [Cites] J Urol. 2005 Jul;174(1):93-6 [15947585.001]
  • [Cites] Cancer. 2011 Dec 1;117(23):5325-33 [21567387.001]
  • [Cites] Cancer Treat Rev. 2006 Dec;32(8):588-93 [17008012.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1172-8 [15700264.001]
  • [Cites] J Urol. 2006 Aug;176(2):781 [16813945.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1369-72 [18505081.001]
  • [Cites] Int J Urol. 2008 Dec;15(12):1080-3 [19120517.001]
  • [Cites] Surg Neurol Int. 2011;2:84 [21748036.001]
  • (PMID = 28638669.001).
  • [ISSN] 2090-6706
  • [Journal-full-title] Case reports in oncological medicine
  • [ISO-abbreviation] Case Rep Oncol Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Tiedje D, Quer O, Breil B, Schrader AJ, Bothe C, Kruse K, Bögemann M, Donner-Banzhoff N, Semjonow A: [Use of the S3 guidelines for early detection of prostate cancer in urological practices]. Urologe A; 2017 Jul;56(7):910-916
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of the S3 guidelines for early detection of prostate cancer in urological practices].
  • [Transliterated title] Anwendung der S3-Leitlinie zur Prostatakrebsfrüherkennung in urologischen Praxen.
  • OBJECTIVES: The German S3 guideline on prostate cancer gives recommendations on early detection of prostate cancer.
  • We developed 23 questions relating to 12 recommendations of the paragraphs of the S3 guidelines dealing with early detection of prostate cancer and prostate biopsy.
  • Reasons for deviations from "strong recommendations" are the following: information about advantages and disadvantages of early detection for prostate cancer, recommendation of a prostate biopsy in case of PSA level ≥4 ng/ml, and indication for repeat biopsy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1994 May;151(5):1283-90 [7512659.001]
  • [Cites] Int J Qual Health Care. 2007 Dec;19(6):349-57 [17872937.001]
  • [Cites] BMJ Open. 2015 Dec 29;5(12 ):e008073 [26715477.001]
  • [Cites] Lancet Oncol. 2010 Aug;11(8):725-32 [20598634.001]
  • [Cites] Urologe A. 2014 Oct;53(10):1500-3 [24984950.001]
  • (PMID = 28280863.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Adherence / Focus groups / Interview / Prostate biopsy / Prostate cancer
  •  go-up   go-down


10. Ilic D, Evans SM, Allan CA, Jung JH, Murphy D, Frydenberg M: Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer: a Cochrane systematic review. BJU Int; 2017 Oct 24;
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer: a Cochrane systematic review.
  • To determine the effects of laparoscopic radical prostatectomy (LRP), or robotic-assisted radical prostatectomy (RARP), compared to open radical prostatectomy (ORP) in men with localised prostate cancer.
  • The primary outcomes were prostate cancer-specific survival, urinary quality of life and sexual quality of life.
  • We included two unique studies with 446 randomised participants with clinically localised prostate cancer.
  • We found no study that addressed the outcome of prostate cancer-specific survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] This article is protected by copyright. All rights reserved.
  • (PMID = 29063728.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; operative / prostate cancer / randomized controlled trials / surgical procedures
  •  go-up   go-down






Advertisement